ALX Oncology Holdings IncNASDAQ:ALXO
- LAST PRICE12.9800
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0000 / 12.9800
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALXO |
|---|---|---|
| 09:32 ET | 3978 | 13.12 |
| 09:34 ET | 1000 | 13.01 |
| 09:36 ET | 1630 | 12.95 |
| 09:38 ET | 100 | 12.875 |
| 09:39 ET | 235 | 13.0014 |
| 09:43 ET | 400 | 13.02 |
| 09:45 ET | 365 | 13 |
| 09:50 ET | 100 | 13.03 |
| 09:52 ET | 130 | 13.0607 |
| 09:59 ET | 500 | 13.215 |
| 10:01 ET | 800 | 13.22 |
| 10:03 ET | 237 | 13.13 |
| 10:06 ET | 100 | 13.18 |
| 10:08 ET | 1200 | 13.16 |
| 10:10 ET | 1225 | 13.135 |
| 10:12 ET | 124 | 13.17 |
| 10:14 ET | 300 | 13.25 |
| 10:15 ET | 800 | 13.37 |
| 10:17 ET | 200 | 13.3254 |
| 10:19 ET | 100 | 13.47 |
| 10:24 ET | 100 | 13.47 |
| 10:26 ET | 1100 | 13.42 |
| 10:28 ET | 100 | 13.52 |
| 10:30 ET | 960 | 13.52 |
| 10:32 ET | 100 | 13.52 |
| 10:33 ET | 300 | 13.45 |
| 10:35 ET | 1000 | 13.48 |
| 10:37 ET | 1425 | 13.45 |
| 10:39 ET | 600 | 13.37 |
| 10:42 ET | 800 | 13.47 |
| 10:44 ET | 200 | 13.47 |
| 10:46 ET | 1500 | 13.475 |
| 10:48 ET | 638 | 13.36 |
| 10:50 ET | 200 | 13.39 |
| 10:51 ET | 400 | 13.43 |
| 10:53 ET | 200 | 13.41 |
| 10:55 ET | 100 | 13.46 |
| 10:57 ET | 300 | 13.4 |
| 11:00 ET | 100 | 13.47 |
| 11:04 ET | 400 | 13.39 |
| 11:08 ET | 2100 | 13.23 |
| 11:09 ET | 283 | 13.2 |
| 11:11 ET | 200 | 13.12 |
| 11:13 ET | 100 | 13.08 |
| 11:15 ET | 400 | 13.085 |
| 11:18 ET | 350 | 13.085 |
| 11:20 ET | 444 | 13.01 |
| 11:22 ET | 892 | 13.06 |
| 11:24 ET | 300 | 13.07 |
| 11:26 ET | 400 | 13 |
| 11:27 ET | 400 | 13.035 |
| 11:31 ET | 345 | 12.955 |
| 11:33 ET | 300 | 12.97 |
| 11:36 ET | 100 | 12.98 |
| 11:38 ET | 400 | 12.91 |
| 11:40 ET | 200 | 12.915 |
| 11:42 ET | 200 | 12.91 |
| 11:44 ET | 100 | 12.88 |
| 11:45 ET | 200 | 12.85 |
| 11:47 ET | 750 | 12.85 |
| 11:49 ET | 2182 | 12.81 |
| 11:51 ET | 200 | 12.765 |
| 11:54 ET | 700 | 12.86 |
| 11:56 ET | 200 | 12.78 |
| 11:58 ET | 600 | 12.77 |
| 12:00 ET | 400 | 12.795 |
| 12:02 ET | 200 | 12.77 |
| 12:03 ET | 200 | 12.83 |
| 12:05 ET | 200 | 12.84 |
| 12:07 ET | 100 | 12.8628 |
| 12:16 ET | 1400 | 12.76 |
| 12:18 ET | 503 | 12.83 |
| 12:21 ET | 450 | 12.87 |
| 12:23 ET | 600 | 12.89 |
| 12:25 ET | 100 | 12.9 |
| 12:34 ET | 300 | 12.95 |
| 12:36 ET | 200 | 12.97 |
| 12:38 ET | 2117 | 13.05 |
| 12:41 ET | 476 | 12.995 |
| 12:45 ET | 350 | 12.95 |
| 12:48 ET | 200 | 12.96 |
| 12:50 ET | 100 | 12.96 |
| 12:52 ET | 600 | 12.97 |
| 12:54 ET | 500 | 12.9604 |
| 12:57 ET | 200 | 13.02 |
| 12:59 ET | 3056 | 12.92 |
| 01:01 ET | 394 | 12.94 |
| 01:06 ET | 300 | 12.9 |
| 01:10 ET | 1395 | 12.86 |
| 01:12 ET | 100 | 12.86 |
| 01:15 ET | 100 | 12.865 |
| 01:17 ET | 100 | 12.84 |
| 01:19 ET | 1300 | 12.92 |
| 01:28 ET | 400 | 12.88 |
| 01:32 ET | 300 | 12.88 |
| 01:33 ET | 561 | 12.88 |
| 01:35 ET | 852 | 12.86 |
| 01:37 ET | 200 | 12.88 |
| 01:42 ET | 400 | 12.86 |
| 01:44 ET | 200 | 12.88 |
| 01:48 ET | 200 | 12.85 |
| 01:50 ET | 200 | 12.83 |
| 01:51 ET | 100 | 12.825 |
| 01:53 ET | 100 | 12.83 |
| 01:55 ET | 200 | 12.81 |
| 02:00 ET | 200 | 12.77 |
| 02:02 ET | 700 | 12.78 |
| 02:04 ET | 400 | 12.79 |
| 02:08 ET | 775 | 12.76 |
| 02:09 ET | 100 | 12.78 |
| 02:15 ET | 605 | 12.78 |
| 02:22 ET | 100 | 12.81 |
| 02:24 ET | 225 | 12.81 |
| 02:27 ET | 3147 | 12.85 |
| 02:29 ET | 100 | 12.86 |
| 02:31 ET | 600 | 12.82 |
| 02:33 ET | 599 | 12.81 |
| 02:36 ET | 100 | 12.84 |
| 02:42 ET | 100 | 12.79 |
| 02:44 ET | 100 | 12.76 |
| 02:45 ET | 300 | 12.79 |
| 02:49 ET | 300 | 12.745 |
| 02:51 ET | 400 | 12.755 |
| 02:54 ET | 300 | 12.72 |
| 02:56 ET | 100 | 12.73 |
| 03:00 ET | 200 | 12.75 |
| 03:02 ET | 105 | 12.79 |
| 03:03 ET | 100 | 12.79 |
| 03:05 ET | 400 | 12.77 |
| 03:09 ET | 400 | 12.755 |
| 03:18 ET | 400 | 12.77 |
| 03:20 ET | 100 | 12.755 |
| 03:21 ET | 300 | 12.75 |
| 03:25 ET | 550 | 12.77 |
| 03:27 ET | 100 | 12.77 |
| 03:30 ET | 100 | 12.805 |
| 03:32 ET | 800 | 12.82 |
| 03:34 ET | 200 | 12.82 |
| 03:36 ET | 100 | 12.84 |
| 03:39 ET | 1000 | 12.825 |
| 03:41 ET | 100 | 12.815 |
| 03:43 ET | 200 | 12.82 |
| 03:45 ET | 2100 | 12.86 |
| 03:48 ET | 400 | 12.84 |
| 03:50 ET | 506 | 12.88 |
| 03:52 ET | 1500 | 12.92 |
| 03:54 ET | 500 | 12.92 |
| 03:56 ET | 1700 | 12.96 |
| 03:57 ET | 4063 | 13.01 |
| 03:59 ET | 19319 | 12.98 |
Yesterday
First Patient Dosed in ALX Oncology's Mid-Stage Trial of Colorectal Cancer Combination Therapy, from 17 hours ago by MT Newswires
17 hours ago by MT NewswiresBRIEF-Alx Oncology Announces First Patient Dosed In Phase 2 Investigator-Sponsored Trial Of Evorpacept , from 20 hours ago by Thomson Reuters
20 hours ago by Thomson ReutersALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer, from 21 hours ago by GlobeNewswire
21 hours ago by GlobeNewswire
Aug 9, 2022
--Cantor Fitzgerald Adjusts ALX Oncology Holdings' Price Target to $32 from $60, Maintains Overweight Rating, from 12:22PM ET on Tuesday Aug 09, 2022 by MT Newswires
12:22PM ET on Tuesday Aug 09, 2022 by MT Newswires--Credit Suisse Lowers ALX Oncology Holdings' PT to $38 from $43, Notes Increased Discount Rate to Reflect Greater Uncertainty on Interest Rate/Inflation; Keeps Outperform Rating, from 9:59AM ET on Tuesday Aug 09, 2022 by MT Newswires
9:59AM ET on Tuesday Aug 09, 2022 by MT Newswires
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ALX Oncology Holdings Inc | 521.2M | -4.8x | --- |
Akero Therapeutics Inc | 516.2M | -4.0x | --- |
Vera Therapeutics Inc | 529.9M | -9.6x | --- |
Inovio Pharmaceuticals Inc | 595.5M | -1.6x | --- |
Centessa Pharmaceuticals PLC | 446.7M | -1.7x | --- |
Edgewise Therapeutics Inc | 519.4M | -8.7x | --- |
Company Information
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company. The Company is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. It is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).
Contact Information
- Headquarters
- 323 Allerton AvenueSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-466-7125
- Fax
- 302-655-5049
Executives
- Executive Chairman of the Board
- Corey Goodman
- President, Chief Executive Officer, Director
- Jaume Pons
- Chief Financial Officer, Principal Accounting Officer
- Peter Garcia
- Chief Accounting Officer, Vice President - Finance
- Shelly Pinto
- Chief Medical Officer, Director
- Sophia Randolph
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $521.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 40.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.72 |
Book Value | $8.94 |
P/E Ratio | -4.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
